Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526341 · ClinicalTrials.gov registry record
Post Market Clinical Follow Up Study for ReliaTack™ Articulating Reloadable Fixation Device With Deep Purchase Tacks
A clinical trial, sponsored by Medtronic - MITG.
- Completed
- Registry status
- 116
- Enrollment target
NCT03526341: Completed study, sponsored by Medtronic - MITG.
NCT03526341 is a clinical trial that has completed, run by Medtronic - MITG. The registered enrollment target is 116 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03526341 has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- 116 participants
- Enrollment target
Study Summary
A post-market clinical follow-up study for ReliaTack™ articulating reloadable fixation device with deep purchase tacks
Primary Outcome
Safety will be assessed as the proportion of subjects with SADE's/AEs
Interventions
- DEVICE ReliaTack™ Articulating Reloadable Fixation Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2018-04-25 |
| Est. Completion | 2019-09-10 |
What the finished NCT03526341 record still lists
NCT03526341 is an observational study that tracks outcomes without assigning an intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ReliaTack™ Articulating Reloadable Fixation Device is the first listed.
NCT03526341 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03526341 about?
NCT03526341 is a clinical study titled "Post Market Clinical Follow Up Study for ReliaTack™ Articulating Reloadable Fixation Device With Deep Purchase Tacks". A post-market clinical follow-up study for ReliaTack™ articulating reloadable fixation device with deep purchase tacks
What is the current status of trial NCT03526341?
This trial is currently completed. The enrollment target is 116 participants. The study started on 2018-04-25. Estimated completion is 2019-09-10.
What interventions are being tested in trial NCT03526341?
The interventions under investigation include: ReliaTack™ Articulating Reloadable Fixation Device (DEVICE).
Who is sponsoring clinical trial NCT03526341?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI